Trials / Completed
CompletedNCT00058539
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
A Phase II, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Omnitarg (Pertuzumab) in Subjects With Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuMAb 2C4 (pertuzumab) |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2003-04-09
- Last updated
- 2015-06-23
- Results posted
- 2015-06-23
Source: ClinicalTrials.gov record NCT00058539. Inclusion in this directory is not an endorsement.